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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
Bimuno
® GOS and reducing gastro-intestinal discomfort pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following  an  application  from  Clasado  Limited,  submitted  for  authorisation  of  a  health  claim  pursuant  to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of  Malta, the EFSA Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation 
of  a  health  claim  related  to  Bimuno
®  GOS  and  reducing  gastro-intestinal  discomfort.  The  food  constituent, 
Bimuno
® GOS, a mixture of β-galacto-oligosaccharides, which is the subject of the health claim, is sufficiently 
characterised. The claimed effect proposed by the applicant is “reduce bloating, flatulence and abdominal pain. 
These effects can be described collectively as abdominal discomfort” and the target population proposed by the 
applicant  is  the  general  adult  population.  Reducing  gastro-intestinal  discomfort  is  a  beneficial  physiological 
effect. A health claim on Bimuno
® GOS and reducing gastro-intestinal discomfort has already been assessed by 
the  Panel  with  an  unfavourable  outcome.  The supplementary information submitted by the applicant  in this 
application did not provide evidence that could be used for the scientific substantiation of this claim.  
© European Food Safety Authority, 2013 
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SUMMARY 
Following  an  application  from  Clasado  Limited,  submitted  for  authorisation  of  a  health  claim 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Malta, the 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on 
the scientific substantiation of a health claim related to Bimuno
® GOS and reducing gastro-intestinal 
discomfort. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The food constituent that is the subject of the health claim is Bimuno
® GOS, a mixture of β-galacto-
oligosaccharides, which is produced through conversion of lactose by enzymes from Bifidobacterium 
bifidum NCIMB 41171. The Panel considers that Bimuno
® GOS is sufficiently characterised.  
The claimed effect proposed by the applicant is “reduce bloating, flatulence and abdominal pain. 
These effects can be described collectively as abdominal discomfort”. The target population proposed 
by the applicant is the general adult population. The Panel considers that reducing gastro-intestinal 
discomfort is a beneficial physiological effect.  
The applicant identified five human intervention studies, three non-human studies and one review 
publication as being pertinent to the health claim. 
A health claim on Bimuno
® GOS and reducing gastro-intestinal discomfort has already been assessed 
by the Panel with an unfavourable outcome.  
All the references, except for the review publication, provided by the applicant for the scientific 
substantiation of this claim were already considered in the previous assessment. The Panel notes that 
the narrative review does not provide original data in addition to the individual studies submitted for 
substantiation.  Additional  information  in  relation  to  two  human  intervention  studies  was  also 
provided. The Panel notes that the additional information provided on these studies did not address 
important methodological limitations which were identified by the Panel in its previous Opinion. The 
Panel considers that no conclusions can be drawn from these studies for the scientific substantiation 
of the claim.   
A health claim on Bimuno
® GOS and reducing gastro-intestinal discomfort has already been assessed 
by  the  Panel  with  an  unfavourable  outcome.  The  supplementary  information  submitted  by  the 
applicant did not provide evidence that could be used for the scientific substantiation of this claim.  
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BACKGROUND 
Regulation (EC) No 1924/2006
4 harmonises the provisions that relate to nutrition and health claims , 
and establishes rules governing the Community authorisation of health claims made on foods.  As a 
rule, health claims are prohibited unless they comply with the general and specific  requirements of 
this Regulation, are authorised in accordance with this Regulation , and are included in the lists of 
authorised claims provided for in Articles 13  and 14 thereof. In particular,  Article 13(5) of this  
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to chi ldren’s  development  and  health)  which  are  based  on  newly  developed 
scientific  evidence,  or  which  include  a  request  for  the  protection  of  proprietary  data,  to  the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted  claims  referred  to  in  Article 13(3)  shall  be  submitted  by  the  applicant  to  the  national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 12/12/2012. 
  The  scope  of  the  application  was  proposed  to  fall  under  a  health  claim  based  on  newly 
developed  scientific  evidence.  The  application  included  a  request  for  the  protection  of 
proprietary data. 
  On 21/01/2013, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
  On 07/02/2013, EFSA received the missing information as submitted by the applicant. 
  The scientific evaluation procedure started on 20/02/2013. 
  On 25/04/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application and the clock 
was  stopped  on  03/05/2013,  in  compliance  with  Article  18(3)  of  Regulation  (EC)  No 
1924/2006. 
  On  15/05/2013,  EFSA  received  the  requested  information  (which  was  made  available  to 
EFSA in electronic format on 13/05/2013) and the clock was restarted, in compliance with 
Article 18(3) of Regulation (EC) No 1924/2006. 
  During  its  meeting  on  30/05/2013,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted an opinion on the scientific substantiation of a health claim related to Bimuno
® GOS 
and reducing gastro-intestinal discomfort. 
TERMS OF REFERENCE 
EFSA  is  requested  to  evaluate  the  scientific  data  submitted  by  the  applicant  in  accordance  with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to:  Bimuno
® GOS and reducing 
gastro-intestinal discomfort. 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. Bimuno
® GOS and reducing gastro-intestinal discomfort  
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EFSA DISCLAIMER 
The  present  opinion  does  not  constitute,  and  cannot  be  construed  as,  an  authorisation  for  the 
marketing of Bimuno
® GOS, a positive assessment of its safety, nor a decision on whether Bimuno
® 
GOS is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen 
in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. Bimuno
® GOS and reducing gastro-intestinal discomfort  
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Clasado Limited, Regent House, Office 25, Bisazza Street, Sliema, 
SLM 1641, Malta. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006 for seven published studies (Tzortzis et al., 2005a, b; Goulas et al., 
2007; Depeint et al., 2008; Vulevic et al., 2008; Silk et al., 2009; Drakoularakou et al., 2010) and one 
unpublished  study  by  Vulevic  et  al.  The  application  also  includes  a  request  for  protection  of 
proprietary data for analytical and stability data pertaining  to the manufacturing process. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituents that are the subject of the health claim are galacto-
oligosaccharides  from  Bimuno
®
  (Bimuno
®  GOS),  which  are  a  mixture  of  β-linked  galacto-
oligosaccharides (β-1→3, β-1→4, β-1→6) with a degree of polymerisation ranging between 2 and 5, 
and α-linked galacto-oligosaccharides (α-1→6) with a degree of polymerisation of 2. 
Health relationship as claimed by the applicant 
According to the applicant, Bimuno
® GOS acts to reduce bloating, flatulence and abdominal pain. 
These effects can be described collectively as “abdominal discomfort”.   
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Regular daily consumption 
of 1.37 g galacto-oligosaccharides from Bimuno
® may reduce abdominal discomfort”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, 1.37 g of galacto-oligosaccharides from Bimuno
® should be consumed 
once daily for a minimum of 7 days.  
The target population as proposed by the applicant is the general male and female adult population. 
ASSESSMENT 
1.  Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is Bimuno
® GOS, a mixture of β-galacto-
oligosaccharides, which is produced through conversion of lactose by enzymes from Bifidobacterium 
bifidum NCIMB 41171.  
Based on chemical analyses that were provided on  five batches, the Bimuno
® powder contains a 
mixture of β-galacto-oligosaccharides (Bimuno
® GOS, 47-53 %), lactose (25-35 %), glucose (6-10 %) 
and galactose (4-7 %). 
Bimuno
® GOS comprises a mixture of β-linked galacto-oligosaccharides (β-1→3, β-1→4, β-1→6) 
and  α-linked  galacto-oligosaccharides  (α-1→6).  The  ratio  of  β-linked  galacto-oligosaccharides  to 
α-linked galacto-oligosaccharides is 93:7.  
The results from the stability tests showed that the Bimuno
® powder was stable for up to two years.  Bimuno
® GOS and reducing gastro-intestinal discomfort  
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The Panel considers that the food constituent, Bimuno
® GOS, which is the subject of the health claim, 
is sufficiently characterised.  
2.  Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “reduce bloating, flatulence and abdominal pain. 
These effects can be described collectively as abdominal discomfort”. The target population proposed 
by the applicant is the general adult population.  
Reducing  gastro-intestinal  discomfort  is  considered  an  indicator  of  improved  gastro-intestinal 
function. Appropriate outcome measures of the claimed effect in human studies include validated 
questionnaire(s)  on  severity  and  frequency  of  symptoms  (e.g.  abdominal  pain,  cramp,  bloating, 
straining, borborygmi [rumbling] and sensation of incomplete evacuation).  
The Panel considers that reducing gastro-intestinal discomfort is a beneficial physiological effect.  
3.  Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed with the following key words: abdominal pain 
prebiotic,  bloating  prebiotic,  flatulence  prebiotic,  IBS  prebiotic,  galactooligosaccharide  bloating, 
galactooligosaccharide digestion, galactooligosaccharide gastrointestinal, bloating colonic microbiota, 
galactooligosaccharide,  trans  galactooligosaccharide,  transgalactooligosaccharide,  transgalacto 
oligosaccharide. No restrictions were applied. Hand searches were also performed by the applicant.  
The applicant identified through the literature search four human intervention studies (Depeint et al. 
2008; Vulevic et al., 2008; Silk et al., 2009; Drakoularakou et al., 2010) and one review publication 
(Tzortzis, 2009) as being pertinent to the health claim. The applicant also provided one unpublished 
human intervention study (Vulevic et al., unpublished) and three non-human studies (Tzortzis et al., 
2005a; Searle et al., 2009, 2010) for the scientific substantiation of the claim. 
All of these human and non-human studies were already submitted by the applicant in a previous 
application  for  the  same  claim,  which  was  assessed  by  the  Panel  with  an  unfavourable  outcome 
(EFSA NDA Panel, 2011) and where the study by Vulevic et al. (unpublished) was referred to as 
Clasado Ltd. (unpublished, claimed as proprietary by the applicant). The present application contains, 
in addition, a non pre-planned intention-to-treat analysis (ITT) of data for the study by Vulevic et al. 
(unpublished), weekly results for secondary outcomes (e.g. defecation, stool consistency, flatulence, 
abdominal pain, bloating, and a composite score of symptoms) in the population of completers of the 
study by Silk et al. (2009), and the narrative review by Tzortzis (2009).  
The Panel notes that in providing a non pre-planned ITT analysis for the study by Vulevic et al. 
(unpublished),  the  applicant  did  not  address  the  important  methodological  limitations  (e.g.  short 
duration of the intervention, and inappropriateness of the original statistical analysis for the cross-over 
design  of  the  study)  of  the  study.  These  important  methodological  limitations  of  the  study  were 
identified by the Panel in its previous Opinion. The Panel considers that no conclusions can be drawn 
from the study by Vulevic et al. (unpublished) for the scientific substantiation of the claim.  
The additional information provided by the applicant for the study by Silk et al. (2009) consists of 
weekly values for some secondary outcomes which were only reported and analysed for the baseline, 
end-of-placebo,  and  end-of-treatment  time  points  in  the  original  study.  The  Panel  notes  that  in 
providing  this additional information, the applicant did not address the important  methodological 
limitations  (e.g.  high  dropout  rate,  multiplicity  of  outcomes  not  taken  into  account  in  the  data 
analysis, statistical methods and results insufficiently described, and no ITT analysis) of the study that 
were identified by the Panel in its previous Opinion. The Panel considers that no conclusions can be 
drawn from the study by Silk et al. (2009) for the scientific substantiation of the claim.  Bimuno
® GOS and reducing gastro-intestinal discomfort  
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The Panel also notes that the narrative review by Tzortzis (2009) does not provide original data in 
addition  to  the  individual  studies  already  submitted  by  the  applicant  in  this  and  the  previous 
application for the scientific substantiation of the claim.  
A health claim on Bimuno
® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) 
of  Regulation  (EC)  No  1924/2006  has  already  been  assessed  by  the  Panel  with an unfavourable 
outcome (EFSA NDA Panel, 2011). The supplementary information submitted by the applicant did 
not provide evidence that could be used for the scientific substantiation of this claim.  
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
  The food constituent, Bimuno
® GOS, which is the subject of the health claim, is sufficiently 
characterised.  
  The claimed effect is “reduce bloating, flatulence and intestinal pain. These effects can be 
described collectively as intestinal discomfort”. The target population as proposed by the 
applicant is the general adult population. Reducing gastro-intestinal discomfort is a beneficial 
physiological effect.  
  A health claim on Bimuno
® GOS and reducing gastro-intestinal discomfort has already been 
assessed with an unfavourable outcome. The supplementary information submitted by the 
applicant did not provide evidence that could be used for the scientific substantiation of this 
claim.  
DOCUMENTATION PROVIDED TO EFSA 
Health  claim  application  on  Bimuno
®  GOS  and  reducing  gastro-intestinal  discomfort  pursuant  to 
Article  13(5)  of  Regulation  (EC)  No  1924/2006  (Claim  serial  No:  0371_MT).  December  2012. 
Submitted by Clasado Limited. 
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GLOSSARY/ABBREVIATIONS 
ITT    Intention-to-treat  
NCIMB  National Collections of Industrial, Marine and Food Bacteria  